Mucosal adjuvants: Opportunities and challenges. - Wikidata - wikimedia - TriplyDB

Mucosal adjuvants: Opportunities and challenges.

Mucosal adjuvants: Opportunities and challenges.

http://www.wikidata.org/entity/Q40682360

about

Curdlan sulfate-O-linked quaternized chitosan nanoparticles: potential adjuvants to improve the immunogenicity of exogenous antigens via intranasal vaccination.Baculovirus Surface Display of Immunogenic Proteins for Vaccine Development

P2860

Q55097822-71B7BF77-00A9-4B9B-A307-5C4E8559F597 Q56514706-11B00CB3-2430-4CF9-9CE8-4A6C1E1980E1

P2860

Mucosal adjuvants: Opportunities and challenges.

http://www.wikidata.org/entity/Q40682360

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Mucosal adjuvants: Opportunities and challenges.

@en

type

label

Mucosal adjuvants: Opportunities and challenges.

@en

prefLabel

Mucosal adjuvants: Opportunities and challenges.

@en

P1433

Q40682360-8E7524D0-3AFE-4548-9960-AD08B2A1BAF4

P1476

Q40682360-A95D398E-F2F8-4F4C-B737-2D3EE4603D75

P2093

Q40682360-62E18241-5BF9-46AE-8A7F-03011EB31B78

P2860

Q40682360-031C37E5-E792-4F8D-A289-A7C3998C0AE8

Q40682360-0E65C1D2-1765-4B91-8C12-E7903DE21CC4

Q40682360-185F5C29-E076-4F1B-8675-78505AFE226C

Q40682360-18AFEDD5-4CDA-486E-85BE-6E5079A961B5

Q40682360-429BDE01-EABA-4F46-9550-8CF907C8340F

Q40682360-467AC47A-5724-4C58-A243-0D80560C63C1

Q40682360-5BE762A7-B918-4D74-8D43-98249B15B058

Q40682360-5DC66E7F-6196-480F-B051-CD5C55000C89

Q40682360-5E3404BB-FF13-4A71-B4FF-82193CD02689

Q40682360-6806432F-F6F8-483D-B0E6-6083764A27F0

P304

Q40682360-68D67355-24D4-4D49-AD51-753DEFD9182D

P31

Q40682360-7688E734-B9E8-454B-9114-F68B945AA707

P356

Q40682360-71356628-B1F3-4D4C-814D-A5356B6092EB

P433

Q40682360-5631E342-F406-44B1-8E7F-E4BE35821BEF

P478

Q40682360-25C10609-FD16-4413-AAAC-EEF89DF11DAA

P577

Q40682360-2E949A16-EEF6-4299-8669-3E582C47F69A

P698

Q40682360-1B4368E3-B624-4031-A787-EE3401DFB9FD

P932

Q40682360-F0590CF5-F377-4761-B2F4-CA57DBD0177A

P356

21645515.2016.1181236

P1433

Human Vaccines & Immunotherapeutics

P1476

Mucosal adjuvants: Opportunities and challenges.

@en

P2093

Lingbin Zeng

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

Molecular signatures of vaccine adjuvants

Boosting vaccine efficacy the natural (killer) way

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Chitosan and its derivatives in mucosal drug and vaccine delivery.

Memory T cells and vaccines.

Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines.

Mast cell-orchestrated immunity to pathogens.

The importance of adjuvant formulation in the development of a tuberculosis vaccine.

P304

2456-2458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21645515.2016.1181236

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27159278

http://www.w3.org/2001/XMLSchema#string

P932

5027714

http://www.w3.org/2001/XMLSchema#string